Press release
Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19
Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens Israel is the second country to reserve supply of LUNAR-COV19 SAN DIEGO,
About this update from Arcturus Therapeutics Holdings Inc.
[{"type":"text","content":"Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens\n Israel is the second country to reserve supply of LUNAR-COV19 SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced a binding term sheet with the Israeli Ministry of Health to supply the Company’s COVID-19 vaccine candidate, LUNAR-COV19. The parties intend to finalize a comprehensive supply agreement within 30 days. “We are very pleased to support Israel’s vaccination strategy by agreeing to supply our novel self-replicating STARR™ mRNA vaccine candidate. The Arcturus team is working diligently to advance LUNAR-COV19 through clinical development and continues to scale up manufacture for the doses required for global distribution,” said Joseph Payne, President & CEO of Arcturus. Delivery to Israel of doses of Arcturus’ COVID-19 vaccine candidate is contingent upon achievement of near term clinical and regulatory milestones and other conditions to be set forth in the definitive supply agreement. The government of Israel is responsible for distributing the vaccine to its citizens subject to approval by their Ministry of Health. The Israeli Ministry of Health is the second government authority to reserve doses of LUNAR-COV19. Arcturus previously announced its partnership with Duke-NUS in Singapore, in which the Company recently received Clinical Trial Application (CTA) approval to proceed with a Phase 1/2 trial. Arcturus continues to scale up manufacturing to potentially produce hundreds of millions of doses across 2020 and 2021. For more information about rights and access to Arcturus’ COVID-19 vaccine candidate, LUNAR-COV19, please contact Arcturus by email at [email protected]. About STARR™ TechnologyThe STARR™ Technology platform combines self-replicating RNA with LUNAR®, a proprietary nanoparticle delivery system, into a single solution to produce proteins inside the human body. The versatility of the STARR™ Technology affords its ability upon delivery into the cell to generate a protective immune response or drive therapeutic protein expression to potentially prevent against or treat a variety ...